INS and metabolic syndrome: Two different randomized clinical trials reported that the combination of omega-3 PUFAs (1200 mg/day to 3000 mg/day, respectively) and lifestyle intervention significantly improved insulin sensitivity, dyslipidemia, and the adiponectin-leptin ratio compared with lifestyle intervention alone [88,89].